Cover Image

Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway

Almonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC). However, the development of resistance inevitably occ...

Full description

Saved in:
Bibliographic Details
Main Authors: Chen Shi (Author), Cong Wang (Author), Zhiwen Fu (Author), Jinmei Liu (Author), Yuanfeng Zhou (Author), Bao Cheng (Author), Cong Zhang (Author), Shijun Li (Author), Yu Zhang (Author)
Format: Book
Published: Elsevier, 2024-03-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items